The Cаrbоhydrаte Respоnse Element Binding Prоtein (ChREBP) is а critical transcription factor involved in regulating genes associated with carbohydrate metabolism, such as those controlling glycolysis and lipogenesis. ChREBP plays a significant role in responding to elevated glucose levels by modulating the expression of key enzymes involved in glucose utilization and storage. In its inactive state, ChREBP resides in the cytosol in a phosphorylated form. This phosphorylation prevents its translocation to the nucleus, thus inhibiting its transcriptional activity. The enzyme protein phosphatase 2A (PP2A) regulates the activation of ChREBP. When ChREBP needs to be activated, PP2A removes one phosphoryl group from ChREBP in the cytosol, which triggers its translocation to the nucleus. Once in the nucleus, PP2A removes a second phosphoryl group from ChREBP, allowing it to form a complex with its binding partner Mlx. The ChREBP-Mlx complex then binds to carbohydrate response elements (ChoREs) in the promoter regions of target genes, activating the transcription of genes involved in carbohydrate metabolism. The activity of PP2A itself is regulated by xylulose-5-phosphate (Xu5P), a pentose phosphate pathway metabolite, which links carbohydrate metabolism to the regulation of ChREBP activity. What is the role of xylulose-5-phosphate (Xu5P) in the regulation of ChREBP?
Reseаrchers hаve been investigаting a nоvel drug designed tо inhibit RNA pоlymerase II, the enzyme responsible for transcribing mRNA in eukaryotic cells. This drug, termed Pol2Block, specifically binds to the enzyme’s active site, preventing the addition of ribonucleotides to the growing RNA strand. In early trials, Pol2Block demonstrated significant effectiveness in halting the growth of rapidly dividing cancer cells. However, it was observed that normal cells were also affected, leading to severe side effects. To reduce these side effects, researchers modified Pol2Block to specifically target cancer cells with a mutation in the p53 tumor suppressor gene, which is commonly found in many types of cancer. The modified drug, Pol2Block-p53, only becomes active in cells lacking functional p53. This was achieved by attaching a molecular "switch" to the drug that is activated in the absence of p53. Initial trials showed that Pol2Block-p53 selectively inhibits RNA polymerase II in cancer cells without significantly affecting normal cells. Researchers then tested the effects of Pol2Block-p53 on HeLa cells (cervical cancer cells) and MCF-7 cells (breast cancer cells). HeLa cells, which contain a p53 mutation, showed a marked decrease in transcription and cell proliferation when treated with Pol2Block-p53. In contrast, MCF-7 cells, which express functional p53, were largely unaffected by the drug. This selective inhibition of cancer cells without harming normal cells represents a potential breakthrough in cancer treatment. Based on the passage, which of the following is the most likely explanation for why Pol2Block-p53 is effective in HeLa cells but not in MCF-7 cells?